What factors do you look at while deciding between a daratumumab-based quadruplet induction versus standard triplet induction such as VRd for newly diagnosed MM?

This is becoming an increasingly thorny issue. A few guidelines to keep in mind:

1) Dara-VRd has only been studied (thus far) in transplant-eligible patients. So this discussion of Dara-VRd vs. VRd is hard to apply to patients without intent for transplant.

2) When you look at the CASSIOPEIA and GRIF...

I agree with Dr. @Dr. First Last's approach. With the Phase 2 GRIFFIN data that we do have available, I prefer to use Dara-RVd for our transplant-eligible population.

For older patients who are not transplant-eligible, we have good phase 3 data from the MAIA trial to support the use of Dara-Rd (plus ...